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Purpose: To investigate the relationship between human papillomavirus (HPV) infec-
tion and prostatitis-related symptoms.
Materials and Methods: All young heterosexual patients with prostatitis-related symp-
toms attending the same Center from January 2005 to December 2010 were eligible 
for this case-control study. Sexually active asymptomatic men were considered as 
the control group. All subjects underwent clinical examination, Meares-Stamey test 
and DNA-HPV test. Patients with prostatitis-related symptoms and asymptomatic men 
were compared in terms of HPV prevalence. Moreover, multivariable Cox proportional 
hazards regression analysis was performed to determine the association between HPV 
infection and prostatitis-related symptoms.
Results: Overall, 814 out of 2,938 patients (27.7%) and 292 out of 1,081 controls (27.0%) 
proved positive to HPV. The HPV genotype distribution was as follows: HR-HPV 478 
(43.3%), PHR-HPV 77 (6.9%), LR-HPV 187 (16.9%) and PNG-HPV 364 (32.9%). The 
most common HPV genotypes were: 6, 11, 16, 26, 51, 53 and 81. No difference was 
found between the two groups in terms of HPV infection (OR 1.03; 95% CI 0.88-1.22; 
p = 0.66). We noted a statistically significant increase in HPV infection over the period 
2005 to 2010 (p < 0.001) in both groups. Moreover, we found a statistically significant 
increase in HPV 16 frequency from 2005 to 2010 (p = 0.002).
Conclusions: This study highlights that prostatitis-like symptoms are unrelated to HPV 
infection. Secondary, we highlight the high prevalence of asymptomatic HPV infection 
among young heterosexual men.
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INTRODUCTION
 Human papillomavirus (HPV) infection is 
one of the most common sexually transmitted in-
fections in both genders (1). HPV infection is the 
main cause of cervical cancer in women and is 
responsible for other cancers such as penile, oral-
-neck and anal cancer in men (2). Men are key to 
the transmission of HPV to women, but relatively 
little is known about the natural history of HPV 
infection in men (3). The prevalence of HPV in ma-
les ranges from 7% to 45% (4), but the majority 
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of studies have been conducted on homosexu-
als, HIV patients or infertile men (5,6). Recently, 
Klinglmair et al. found a high prevalence of HPV 
infection in a cohort of 250 young males, inclu-
ding children (0-10 years), indicating non-sexual 
transmission pathways (7). Genital infection is of-
ten asymptomatic and undiagnosed. In a recent 
study on 2,702 uncircumcised, HIV sero-negative 
males, Rositch et al. found that 51% of them pre-
sented occult HPV infection, of whom 57% with 
HPV multiple types (8). Thus, HPV prevalence data 
in men vary widely depending on the anatomical 
sites sampled, populations studied and analyti-
cal methods used for HPV detection (9). Seve-
ral authors suggest that HPV tends to infect the 
prostatic epithelium (9), however, no correlation 
between symptoms from prostate pathology and 
HPV infection has ever been reported. On the basis 
of HPV DNA PCR findings, it has been suggested 
that the male genitourinary tract, including sperm 
cells, might act as a reservoir for HPV persistence 
and infection (9,10). On the other hand, prostatitis-
-related symptoms are recognized as an important 
socio-economical problem and several sexually 
transmitted infections are linked to the presence 
of prostatitis-related symptoms (11,12). We inves-
tigated HPV infection prevalence in young hete-
rosexual males with prostatitis-related symptoms 
in order to find a possible relationship between 
HPV infection and prostatitis-related symptoms. 
The present case-control study aimed to determine 
whether HPV infection could be considered a risk 
factor of prostatitis-related symptoms in young 
heterosexual males.
MATERIALS AND METHODS
Study design
 The study population consisted of two 
groups of young heterosexual men attending the 
same Sexually Transmitted Diseases Center from 
January 2005 to December 2010: Group A (cases), 
all consecutive patients with prostatitis-related 
symptoms, and Group B (controls), sexually ac-
tive asymptomatic men whose female partners 
were infected with Chlamydia trachomatis. All 
patients and controls were screened for this stu-
dy using the 4-glass Meares-Stamey test and and 
DNA-HPV test. All controls underwent 4-glass 
Meares-Stamey test and DNA-HPV test due to the 
fact that they were partners of female affected by 
Chlamydia trachomatis infection. This is the rou-
tinely practice in our STDs Centre. Clinical and 
laboratory findings for the two groups were com-
pared. This case-control study aimed to determine 
whether exposure to HPV infection could be as-
sociated with clinical outcomes such as the pre-
sence of prostatitis-related symptoms. This study 
was conducted in line with the STROBE statement 
(http://www.strobe-statement.org). Italian law 
does not require authorization from the institutio-
nal review board (IRB), nor informed consent from 
the patients (http://www.agenziafarmaco.gov.it/
it/content/linee-guida-studi-osservazionali). Ne-
vertheless, our study was conducted in line with 
the Good Clinical Practice guidelines and with the 
ethical principles laid down in the latest version of 
the Declaration of Helsinki.
Inclusion and exclusion criteria
 Group A patients were selected consecu-
tively from a series of individuals suffering from 
chronic prostatitis-related symptoms for over 6 
months, as defined in the latest version of the 
European Association of Urology (EAU) guideli-
nes (13). In particular, the patients were selected 
and categorized according to Nickel’s criteria for 
perineal or ejaculatory pain. All enrolled patients 
must have had a pain score equal to or greater 
than 4, defined as “mild prostatitis” if the pain 
score ranged from 4 to 7 and “moderate or severe 
prostatitis” if the score was 8 or greater (14). Sub-
jects under 18 and over 45 years of age, affected 
by major concomitant diseases, with known ana-
tomical abnormalities of the urinary tract or with 
evidence of other urological diseases, and diag-
nosed with genital or anal warts, participating in 
an HPV vaccine study, were excluded as well as 
patients with suspected urothelial cell carcinoma 
at cytological urine analysis or who had previou-
sly undergone prostate surgery. Group B patients 
were included in the study only if asymptomatic 
and falling within the age range of 18 - 45 years, 
and with no known major concomitant diseases. 
All homosexuals were excluded from both study 
groups due to their increased risk of exposure to 
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HPV infection. Moreover, all patients have been 
asked about the sexual experience and the circu-
mcision status. A detailed assessment about the 
sexual behavior has been carried out.
Study schedule and sample collection
 We retrospectively collected anamnes-
tic, clinical, laboratory and microbiological data 
for 6,743 patients from our database (Advanced 
PROSTATitis DataBase, Microsoft Access for-
mat). From these, we excluded 2,725 due to lack 
of data. Finally we considered 4,018 individuals 
for this study (2,938 patients and 1,081 controls) 
(Figure-1). 2,938 patients with prostatitis-related 
symptoms were assigned to Group A while 1,080 
to Group B. We collected the validated Italian ver-
sions of the NIH Chronic Prostatitis Symptom In-
dex (NIH-CPSI) (15) and the International Prosta-
tic Symptom Score (IPSS) (16) for all patients and 
controls. All microbiological data were collected 
in accordance with indications described by Ma-
zzoli et al. fi rst void early morning urine (VB1), 
mid-stream urine (VB2), expressed prostatic se-
cretion (EPS), post prostate massage urine (VB3) 
and total ejaculate (TE) (12). In order to evaluate 
the HPV infection in the urethra, a urethral swab 
(UR_SW) was taken from all subjects. Moreover, 
in our Centre we did not routinely performed the 
HPV specifi c antibodies.
Laboratory procedures and microbiological con-
siderations
 Microbiological cultures were performed in 
accordance with the methods described by Motri-
ch et al. (17). DNA extraction and purifi cation of 
all biological materials was performed using the 
DNeasy® Tissue Kit by QIAGEN Spa, Italy. 200µL of 
pellet was pre-incubated overnight with proteinase 
k and the next day extracted and purifi ed follo-
wing the manufacturer’s instructions. All the bio-
logical material from the whole study population 
was tested for the presence of genital HPV using 
Alpha Watch HPV, Alphagenic-Diaco-Biotechnolo-
gy, Trieste, Italy. All biological materials from our 
patients were analyzed by Inno-Lipa HPV Genoty-
ping Extra (Innogenetics, Italy). Amplifi cation of a 
Figure 1 - The fi gure shows the Study fl ow-chart.
Data collection
fron Database
Assessed for eligibility (n=6,743)
Allocated to Group A (n= 2,938)
(patients with prostatitis-related symptoms)
Allocated to Group B (n= 1,081)
(controls)
Excluded (n=2,725)
[Lack of data (n= 2,725)]
Allocation and
Analysis
Evaluated (n=4,018)
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fragment of the b-globin gene served as an internal 
quality control for each specimen. In accordance to 
Munoz et al., we classified the following genotypes 
as high risk-HPV (HR-HPV): 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68, 73, and 82; as probable 
high-risk (PHR-HPV): 26, 53, and 66; and as low 
risk (LR-HPV): 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 
8118. HPV positive samples which did not hybridize 
with any of the type-specific probes were referred to 
as positive non genotype-able (PNG-HPV) (18). Ac-
cording to Giuliano et al., a participant was conside-
red positive for ‘‘any HPV’’ if he tested HPV-positive 
by PCR or by genotyping (19). The category ‘‘any 
oncogenic type’’ included those who were positive 
for only oncogenic genotypes and those who were 
positive for both oncogenic and non-oncogenic 
types. Only single or multiple infections with non-
-oncogenic HPV types were classified as ‘‘any non-
-oncogenic type’’. This STDs laboratory is registered 
by the United Kingdom National External Quality 
Assessment (NEQUAS) for microbiology for mole-
cular detection of Ct (Quality Assurance Laboratory, 
Health Protection Agency Centre for Infection, 61 
Colindale Avenue, London NW 95HT, United King-
dom). All microbiological analyses were performed 
blindly. Following Nickel et al., white blood cell 
(WBC) counts in all biological samples were carried 
out, though not considered in this study (20).
Statistical analysis and considerations
Pearson’s coefficient was adopted to evalu-
ate the correlation between the different parameters 
in all patients, and Fisher’s exact test or Chi-square 
test (χ2) used to assess statistical significance with 
p < 0.05 accepted as significant. Multivariable Cox 
proportional hazards regression analysis was then 
performed to determine the association between 
HPV infection and prostatitis-related symptoms. 
The ANOVA test was applied to evaluate the di-
fference between the two groups in terms of NIH-
-CPSI and IPSS questionnaire scores. The Bonfer-
roni adjustment test was also used at the second 
stage of the analysis of variance. Odds ratio (OR) 
and 95% confidence intervals (CI) were calculated 
to determine the significance of differences. Statis-
tical significance was set at p < 0.05. All reported 
p-values are two-sided. All statistical analyses were 
performed by using SPSS 11.0 for Apple-Macintosh 
(SPSS, Inc., Chicago, Illinois).
RESULTS
 Data from 4,018 subjects were collected and 
analysed. A total of 2,938 patients were assigned to 
Group A (cases, prostatitis-related symptoms) while 
1,080 to Group B (controls, asymptomatic subjects).
Clinical and microbiological evaluation
 Detailed information about demographic 
and socioeconomic variables, medical history and 
clinical data at enrollment are given in Table-1. All 
cases revealed a mean symptom time of 15.4 mon-
ths (range 10-26 months) but none presented genital 
or anal warts on physical examination. Overall, 814 
out of the 2,938 patients (27.7%) and 292 out of the 
1,081 controls (27.0%) proved positive to HPV (Odds 
ratio [OR] 1.03; 95% CI 0.88-1.22; p = 0.66). The 
HPV genotype distribution is as follows: HR-HPV 
478 (43.3%), PHR-HPV 77 (6.9%), LR-HPV 187 
(16.9%) and PNG-HPV 364 (32.9%). Data stratifica-
tion according to age is given for both groups in Ta-
bles 2 and 3. In Group A, 28 out of 814 (3.4%) were 
also positive to Chlamydia trachomatis vs 31 out of 
292 (10.6) in Group B, with a statistically significant 
difference (p < 0.001; Chi square 20.5; df = 1).
HPV prevalence and genotype distribution
Patients with prostatitis-related symptoms 
(Group A)
HPV genotype distribution was as follows: 
HR-HPV 417 (51.3%), PHR-HPV 70 (8.7%), LR-HPV 
64 (7.7%) and PNG-HPV 263 (32.3%). The most 
common HPV genotypes were: 16 (18%), 31 (29%) 
and 33 (24%). HPV genotype distribution stratified 
per year is detailed in Table-2. HPV 16 and PNG-
-HPV frequencies were found to significantly in-
crease over the period 2005 to 2010 (p = 0.002 and 
p = 0.003, respectively). No statistically significant 
increase in frequency was found for the other HPV 
types. In addition, there was a decrease in HR-HPV 
and PHR-HPV incidence in 2009.
Asymptomatic patients (Group B)
 HPV genotype distribution for asymp-
tomatic subjects was as follows: HR-HPV 116 
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Table 1 - Patient’s sociodemographic anamnestic, clinical characteristics at enrolment time.
No. of total enrolled subjects 4,019
Patients Controls
2,938 1,081 p
Median age (± SD*) 35.7 ± 5.8 36.0 ± 5.9 0.14
Educational level
Primary school - -
Secondary school 2,001 (68.1) 716 (66.2) 0.25
Post-secondary education 937 (31.9) 365 (33.8)
Sexually active (past month) 2,899 (98.6) 1,070 (99.0) 0.45
Sexual behavior
1 partner 2,376/2,899 (81.9) 881/1,070 (82.3) 0.81
> 1 partners 523/2,899 (18.1) 189/1,070 (17.7)
Contraceptive use 1,903/2,899 (65.6) 693/1,070 (64.7) 0.59
Condom 1,302/1,903 (68.5) 479/693 (69.2) 0.77
Coitus interruptus 601/1,903 (31.5) 214/693 (29.8)
Clinical data
Clinical presentation
Dysuria 1,292 (43.9) - -
Urgency 1,478 (50.3) - -
Dysuria + Frequency 1,123 (38.2) - -
Burning 981 (33.3) - -
Pain
Perineal 1,341 (45.6) - -
Scrotal 742 (25.2) - -
Suprapubic 311 (10.5) - -
Lower Abdominal 214 (7.2) - -
Start of CP# history (months) 15.4 ± 8.2 - -
Symptoms Score at baseline (mean) (range)
NIH-CSPI§ 18.9 (13-26) 2.8 (0-3) < 0.001
IPSS† 17.3 (1-24) 2.2 (0-6) < 0.001
SD* = Standard Deviation; CP # = Chronic prostatitis; NIH-CSPI§ = NIH- Chronic Prostatitis Symptom Index; IPSS† = International Prostatic Symptom Score.
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(39.7%), PHR-HPV 26 (8.9%), LR-HPV 26 (8.9%) 
and PNG-HPV 124 (42.5%). The most common HPV 
genotypes were: 11 (17.2%) and 31 (30.2%). Table-3 
shows HPV genotype distribution per year. There was 
no statistically significant increase in PCN-HPV pre-
valence from 2005 to 2010 (p = 0.68). As in Group 
A, we found a decrease in HR-HPV and PHR-HPV 
incidence in 2009. There was a statistically signifi-
cant increase in HPV prevalence from 2005 to 2010 
(p < 0.001) in both patients and controls (Figure-2). 
On the other hand, there was no increase in HR-HPV 
infection prevalence from 2005 to 2010 (Figure-3).
HPV incidence and distribution per bio-
logical sample
 We collected 18,351 samples from the all pa-
tients. We found 2,276 positive samples from 1,106 
subjects (814 Group A and 292 Group B) (Table-4). 
There was no difference in HPV detection rate among 
VB1, TE and UR_SW were found (p = 0.30), nor be-
Table 2 - Summary results for grouped HPV type distribution by years (Patients).
Year Total
2005 2006 2007 2008 2009 2010
Number of patients 584 446 523 547 427 411 2,938
HPV positive 86 (14.7) 123 (27.5) 112 (21.4) 183 (33.4) 134 (31.3) 176 (42.8) 814 (27.7)
Sub-analysis on HPV positive patients
HR-HPV 62 (72.0) 81 (65.8) 79 (70.6) 86 (46.9) 26 (19.4) 83 (47.1) 417 (51.2)
PHR-HPV 5 (5.8) 11 (8.9) 5 (4.4) 20 (10.9) 5 (3.8) 24 (13.6) 70 (8.6)
LR-HPV 4 (4.6) 7 (5.7) 8 (7.2) 12 (6.6) 24 (17.9) 9 (5.2) 64 (7.8)
PNG-HPV 15 (17.4) 24 (19.6) 20 (17.8) 65 (35.6) 79 (58.9) 60 (34.1) 263 (32.4)
HR-HPV = High-Risk HPV; PHR-HPV = Probable High-Risk HPV; LH-HPV = Low-Risk HPV; PNG-HPV = Positive Non Genotype-able HPV.
Table 3 - Summary results for grouped HPV type distribution by years (Controls).
Year Total
2005 2006 2007 2008 2009 2010
Number of patients 205 171 189 165 134 217 1,081
HPV positive 33 (16.0) 42 (24.5) 37 (19.5) 51 (30.9) 39 (29.1) 90 (41.4) 292 (27.0)
Sub-analysis on HPV positive  patients
HR-HPV 15 (45.3) 18 (42.8) 17 (45.9) 19 (37.2) 8 (20.5) 39 (43.3) 116 (39.7)
PHR-HPV 4 (12.1) 4 (9.5) 5 (13.5) 3 (5.9) 1 (2.6) 9 (10) 26 (8.9)
LR-HPV 2 (6.0) 5 (11.9) 3 (8.1) 9 (17.6) 2 (5.2) 5 (5.5) 26 (8.9)
PNG-HPV 12 (36.6) 15 (35.8) 12 (32.5) 20 (39.3) 28 (71.7) 37 (41.2) 124 (42.5)
HR-HPV = High-Risk HPV; PHR-HPV = Probable High-Risk HPV; LH-HPV = low-risk HPV; PNG-HPV = positive non genotype-able HPV.
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Figure 2 - The figure shows the prevalence of HPV-positive 
patients and the High-Risk-HPV positive patients in both 
patients and controls.
Figure 3 - The figure shows the prevalence of all HPV-
positive patients stratified by risk class.
Table 4 - HPV prevalence according to collected biological samples and years.
Sample VB1 VB2 VB3 TE UR_SW
Year Total
2005 77 2 8 69 81 237
2006 119 5 18 112 118 372
2007 101 9 14 108 105 337
2008 161 12 27 115 169 484
2009 123 6 11 99 129 368
2010 163 5 19 121 170 478
Total 744 39 97 624 772 2,276
VB1 = First void early morning urine; VB2 = Mid-stream urine; VB3 = Expressed prostatic secretion; TE = Total ejaculate; EPS = Expressed prostatic secretion; UR_SW = Urethral swab.
tween VB1 and UR_SW (p = 0.69). We also noted a 
statistically significant difference among VB1, VB2 
and VB3 (p < 0.001) (Figure-4). We did not include 
the EPS data in the analysis due to the limited num-
ber of samples collected (81 out of 814 patients for 
Group A, 18 out of 292 controls for Group B).
HPV and other related risk factors
No significant difference in overall HPV pre-
valence was found in the different age categories in 
either group (Table-1). Finally, we found a higher 
HR-HPV prevalence in Group A compared with 
Group B patients (39.7% vs 51.2%) (p = 0.008). 
Total Patients
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There was no difference in terms of sexual beha-
vior or use of contraceptives (Table-1).
DISCUSSION
 HPV transmission normally occurs through 
sexual intercourse with commonly recognized in-
fection distribution. In the absence of any obvious 
clinical manifestations, such as genital warts, a male 
is often considered as a healthy disease-carrier (21). 
Genital infection is often asymptomatic in both 
genders, although genital warts can generate local 
symptoms such as burning, itching and occasional 
bleeding (22). In the present study, no significant 
difference in prevalence of HPV infection-related 
symptoms was found between the two groups, al-
though approximately 33% of Group A patients 
complained of burning during micturition. This 
symptom should be considered part of chronic pel-
vic pain syndrome, since all these patients had VB2 
samples negative for bacteria at the 4-glass Meares-
-Stamey test. The cohort of young heterosexual ma-
les with prostatitis-related symptoms was selected 
on the basis of the recent literature on HPV reporting 
a high prevalence of infection (over 70% of cases) in 
men between 17 and 45 years of age. Similarly, the 
control group was selected from asymptomatic and 
sexually active males, because their female sexual 
partners were infected with Chlamydia trachomatis, 
thus more exposed to the risk of developing sexu-
ally transmitted infections. Homosexuals were ex-
cluded from the study due to their increased risk of 
developing HPV infection (23). Several authors have 
demonstrated the presence of HPV in the semen, al-
though none of them has suggested any relationship 
with male infertility. Perino et al. showed that the 
abortion rate in male-infected couples is significan-
tly higher (66.7%) than in normal couples (15%) (24). 
Indeed, viral bodies adhere to spermatozoa, subse-
quently reducing their motility (25). HPV could then 
be transmitted from men to women during sexu-
al intercourse through sexual “contact” as well as 
through biological fluids. Moreover infection of the 
seminal tract (prostate, seminal vesicle, vas deferens) 
could also be hypothesized on the basis of HPV pre-
sence in the semen of asymptomatic patients. Our 
results partially contradict this hypothesis. The HPV 
prevalence was higher in VB1 and urethral swabs 
than in VB2 and VB3 samples. Several authors re-
port HPV prevalence in the urethra ranging from 20 
to 48%, although these data could be influenced by 
either the limited number of subjects evaluated, the 
wide age range of selected subjects or the difference 
in their sexual habits, activity and attitudes. On the 
other hand, for the same reasons, the prevalence of 
HPV infection in the semen has been investigated 
by various authors with conflicting results. Foresta 
et al. found 40.9% prevalence in subjects with in-
fected sexual partners and 2.2% in fertile controls, 
while Nielsen et al. found 5.3% prevalence in 463 
heterosexual men (26,27). Our study confirmed the 
high prevalence of HPV infection (27.7%) in a large 
cohort of young heterosexual men and an increasing 
positive trend of HPV infection over a 5 year period. 
No significant difference in prevalence was found 
between the group with prostatitis-related symp-
toms and the asymptomatic control group, although 
Group A patients exhibited an increased prevalence 
in HR-HPV genotypes. Despite the lack of differen-
ces in sexual behavior or contraceptive use between 
the two groups, the control group would have been 
expected to show a higher rate of HR-HPV infection 
due to their increased risk of developing Chlamydia 
Figure 4 - The figure shows the prevalence of HPV-positive 
biological samples according to each analyzed sample.
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trachomatis co-infection, commonly considered a 
sexually transmitted infection. HPV infection pre-
valence in the control group was independent from 
Chlamydia trachomatis co-morbidity (28). These re-
sults confirm that an increased risk of developing 
HPV infection in young heterosexual men is not re-
lated to the number of sexual partners but to the 
social diffusion of the disease in both genders. This 
is also supported by the increasing trend of HPV in-
fection over the five-year period. The present study 
shows few limitations that should be taken into ac-
count. Firstly, the retrospective nature of this study. 
Secondly, the highly selected patient population due 
to the fact that we have enrolled patients attending 
a specific STDs Centre. Finally, the fact that we have 
no data about the impact of female vaccination on 
HPV male prevalence.
CONCLUSIONS
 In conclusion, we found no correlation 
between the presence of prostatitis-related symp-
toms and HPV infection, highlighting an asymp-
tomatic and increasing prevalence of HPV in 
young heterosexual males.
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